PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients

Bruno Vincenzi; Daniele Santini; Giuseppe Perrone; Francesco Graziano; Fotios Loupakis; Gaia Schiavon; Anna Maria Frezza; Anna Maria Ruzzo; Sergio Rizzo; Pierfilippo Crucitti; Sara Galluzzo; Alice Zoccoli; Carla Rabitti; Andrea Onetti Muda; Antonio Russo; Alfredo Falcone; Giuseppe Tonini

doi:10.1002/jcp.22801

PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients

Bruno Vincenzi, Daniele Santini, Giuseppe Perrone, Francesco Graziano, Fotios Loupakis, Gaia Schiavon, Anna Maria Frezza, Anna Maria Ruzzo, Sergio Rizzo, Pierfilippo Crucitti, Sara Galluzzo, Alice Zoccoli, Carla Rabitti, Andrea Onetti Muda, Antonio Russo, Alfredo Falcone, Giuseppe Tonini

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

PML regulates a wide range of pathways involved in tumorigenesis, such as apoptosis, which is also one of the main mechanisms through which oxaliplatin and fluoropyrimidine exert their antineoplastic activity. The present study aims to investigate PML expression as a predictive factor of oxaliplatin/fluoropyrimidine therapy efficacy. Seventy-four metastatic colorectal cancer patients who received oxaliplatin/floropyrimidine-based first line therapy have been included in this retrospective study. PML expression was assessed by immunohistochemistry. PML down-regulation was detected in 39 (52.7%) patients (14 complete and 25 partial PML loss). RR was significantly lower (25.6%) in patients with PML down-regulation than in patients with preserved PML expression (60%) (P=0.006). Median TTP was 5.5 months when PML was down-regulated versus 11.9 months in case of preserved PML expression (P

Original language	English
Pages (from-to)	927-933
Number of pages	7
Journal	Journal of Cellular Physiology
Volume	227
Issue number	3
DOIs	https://doi.org/10.1002/jcp.22801
Publication status	Published - Mar 2012

ASJC Scopus subject areas

Clinical Biochemistry
Cell Biology
Physiology

Access to Document

10.1002/jcp.22801

Cite this

Vincenzi, B., Santini, D., Perrone, G., Graziano, F., Loupakis, F., Schiavon, G., Frezza, A. M., Ruzzo, A. M., Rizzo, S., Crucitti, P., Galluzzo, S., Zoccoli, A., Rabitti, C., Muda, A. O., Russo, A., Falcone, A., & Tonini, G. (2012). PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients. Journal of Cellular Physiology, 227(3), 927-933. https://doi.org/10.1002/jcp.22801

PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients. / Vincenzi, Bruno; Santini, Daniele; Perrone, Giuseppe; Graziano, Francesco; Loupakis, Fotios; Schiavon, Gaia; Frezza, Anna Maria; Ruzzo, Anna Maria; Rizzo, Sergio; Crucitti, Pierfilippo; Galluzzo, Sara; Zoccoli, Alice; Rabitti, Carla; Muda, Andrea Onetti; Russo, Antonio; Falcone, Alfredo; Tonini, Giuseppe.

In: Journal of Cellular Physiology, Vol. 227, No. 3, 03.2012, p. 927-933.

Research output: Contribution to journal › Article › peer-review

Vincenzi, B, Santini, D, Perrone, G, Graziano, F, Loupakis, F, Schiavon, G, Frezza, AM, Ruzzo, AM, Rizzo, S, Crucitti, P, Galluzzo, S, Zoccoli, A, Rabitti, C, Muda, AO, Russo, A, Falcone, A & Tonini, G 2012, 'PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients', Journal of Cellular Physiology, vol. 227, no. 3, pp. 927-933. https://doi.org/10.1002/jcp.22801

Vincenzi, Bruno ; Santini, Daniele ; Perrone, Giuseppe ; Graziano, Francesco ; Loupakis, Fotios ; Schiavon, Gaia ; Frezza, Anna Maria ; Ruzzo, Anna Maria ; Rizzo, Sergio ; Crucitti, Pierfilippo ; Galluzzo, Sara ; Zoccoli, Alice ; Rabitti, Carla ; Muda, Andrea Onetti ; Russo, Antonio ; Falcone, Alfredo ; Tonini, Giuseppe. / PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients. In: Journal of Cellular Physiology. 2012 ; Vol. 227, No. 3. pp. 927-933.

@article{945750e82263496a9515d6df7cdf9c44,

title = "PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients",

abstract = "PML regulates a wide range of pathways involved in tumorigenesis, such as apoptosis, which is also one of the main mechanisms through which oxaliplatin and fluoropyrimidine exert their antineoplastic activity. The present study aims to investigate PML expression as a predictive factor of oxaliplatin/fluoropyrimidine therapy efficacy. Seventy-four metastatic colorectal cancer patients who received oxaliplatin/floropyrimidine-based first line therapy have been included in this retrospective study. PML expression was assessed by immunohistochemistry. PML down-regulation was detected in 39 (52.7%) patients (14 complete and 25 partial PML loss). RR was significantly lower (25.6%) in patients with PML down-regulation than in patients with preserved PML expression (60%) (P=0.006). Median TTP was 5.5 months when PML was down-regulated versus 11.9 months in case of preserved PML expression (P",

author = "Bruno Vincenzi and Daniele Santini and Giuseppe Perrone and Francesco Graziano and Fotios Loupakis and Gaia Schiavon and Frezza, {Anna Maria} and Ruzzo, {Anna Maria} and Sergio Rizzo and Pierfilippo Crucitti and Sara Galluzzo and Alice Zoccoli and Carla Rabitti and Muda, {Andrea Onetti} and Antonio Russo and Alfredo Falcone and Giuseppe Tonini",

year = "2012",

month = mar,

doi = "10.1002/jcp.22801",

language = "English",

volume = "227",

pages = "927--933",

journal = "Journal of cellular and comparative physiology",

issn = "0021-9541",

publisher = "Wiley-Liss Inc.",

number = "3",

}

TY - JOUR

T1 - PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients

AU - Vincenzi, Bruno

AU - Santini, Daniele

AU - Perrone, Giuseppe

AU - Graziano, Francesco

AU - Loupakis, Fotios

AU - Schiavon, Gaia

AU - Frezza, Anna Maria

AU - Ruzzo, Anna Maria

AU - Rizzo, Sergio

AU - Crucitti, Pierfilippo

AU - Galluzzo, Sara

AU - Zoccoli, Alice

AU - Rabitti, Carla

AU - Muda, Andrea Onetti

AU - Russo, Antonio

AU - Falcone, Alfredo

AU - Tonini, Giuseppe

PY - 2012/3

Y1 - 2012/3

N2 - PML regulates a wide range of pathways involved in tumorigenesis, such as apoptosis, which is also one of the main mechanisms through which oxaliplatin and fluoropyrimidine exert their antineoplastic activity. The present study aims to investigate PML expression as a predictive factor of oxaliplatin/fluoropyrimidine therapy efficacy. Seventy-four metastatic colorectal cancer patients who received oxaliplatin/floropyrimidine-based first line therapy have been included in this retrospective study. PML expression was assessed by immunohistochemistry. PML down-regulation was detected in 39 (52.7%) patients (14 complete and 25 partial PML loss). RR was significantly lower (25.6%) in patients with PML down-regulation than in patients with preserved PML expression (60%) (P=0.006). Median TTP was 5.5 months when PML was down-regulated versus 11.9 months in case of preserved PML expression (P

AB - PML regulates a wide range of pathways involved in tumorigenesis, such as apoptosis, which is also one of the main mechanisms through which oxaliplatin and fluoropyrimidine exert their antineoplastic activity. The present study aims to investigate PML expression as a predictive factor of oxaliplatin/fluoropyrimidine therapy efficacy. Seventy-four metastatic colorectal cancer patients who received oxaliplatin/floropyrimidine-based first line therapy have been included in this retrospective study. PML expression was assessed by immunohistochemistry. PML down-regulation was detected in 39 (52.7%) patients (14 complete and 25 partial PML loss). RR was significantly lower (25.6%) in patients with PML down-regulation than in patients with preserved PML expression (60%) (P=0.006). Median TTP was 5.5 months when PML was down-regulated versus 11.9 months in case of preserved PML expression (P

UR - http://www.scopus.com/inward/record.url?scp=84155184254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84155184254&partnerID=8YFLogxK

U2 - 10.1002/jcp.22801

DO - 10.1002/jcp.22801

M3 - Article

C2 - 21503888

AN - SCOPUS:84155184254

VL - 227

SP - 927

EP - 933

JO - Journal of cellular and comparative physiology

JF - Journal of cellular and comparative physiology

SN - 0021-9541

IS - 3

ER -

PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this